Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Dec;41(12):2781–2785. doi: 10.1128/aac.41.12.2781

A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors.

C Shi 1, J W Mellors 1
PMCID: PMC164210  PMID: 9420060

Abstract

We have developed a new recombinant retroviral system in which a library of infectious molecular clones of human immunodeficiency virus type 1 (HIV-1) is constructed with reverse transcriptase (RT) genes derived from viral RNA sequences in plasma. HIV-1 RT is amplified from plasma HIV-1 RNA by nested RT-PCR and cloned into a RT-defective HIV-1 proviral vector (xxLAI-np), generating 10(3) to 10(4) recombinant proviral clones from each reaction. The bulk cloning products or individual molecular clones are transfected into MT-2 cells to generate infectious virus. The resultant viruses are assayed for drug susceptibility in CD4+ cell lines to determine either the dominant phenotype of the recombinant virus mixture or the phenotypes of the individual viral clones. DNA sequencing of the cloned RT genes can identify mutations associated with phenotypic resistance of clonal mixtures or individual clones. This method can be used to rapidly detect the in vivo emergence of HIV-1 quasispecies resistant to RT inhibitors.

Full Text

The Full Text of this article is available as a PDF (135.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boucher C. A., Keulen W., van Bommel T., Nijhuis M., de Jong D., de Jong M. D., Schipper P., Back N. K. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother. 1996 Oct;40(10):2404–2409. doi: 10.1128/aac.40.10.2404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brun-Vézinet F., Ingrand D., Deforges L., Gochi K., Ferchal F., Schmitt M. P., Jung M., Masquelier B., Aubert J., Buffet-Janvresse C. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. J Virol Methods. 1992 May;37(2):177–188. doi: 10.1016/0166-0934(92)90045-f. [DOI] [PubMed] [Google Scholar]
  3. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol. 1994 Jan 20;47(2):155–169. doi: 10.1016/0006-2952(94)90001-9. [DOI] [PubMed] [Google Scholar]
  4. Gingeras T. R., Prodanovich P., Latimer T., Guatelli J. C., Richman D. D., Barringer K. J. Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus. J Infect Dis. 1991 Dec;164(6):1066–1074. doi: 10.1093/infdis/164.6.1066. [DOI] [PubMed] [Google Scholar]
  5. Harrigan P. R., Kinghorn I., Bloor S., Kemp S. D., Nájera I., Kohli A., Larder B. A. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol. 1996 Sep;70(9):5930–5934. doi: 10.1128/jvi.70.9.5930-5934.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hooker D. J., Tachedjian G., Solomon A. E., Gurusinghe A. D., Land S., Birch C., Anderson J. L., Roy B. M., Arnold E., Deacon N. J. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine. J Virol. 1996 Nov;70(11):8010–8018. doi: 10.1128/jvi.70.11.8010-8018.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Japour A. J., Chatis P. A., Eigenrauch H. A., Crumpacker C. S. Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3092–3096. doi: 10.1073/pnas.88.8.3092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Japour A. J., Mayers D. L., Johnson V. A., Kuritzkes D. R., Beckett L. A., Arduino J. M., Lane J., Black R. J., Reichelderfer P. S., D'Aquila R. T. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother. 1993 May;37(5):1095–1101. doi: 10.1128/aac.37.5.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kaye S., Comber E., Tenant-Flowers M., Loveday C. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Hum Retroviruses. 1995 Oct;11(10):1221–1225. doi: 10.1089/aid.1995.11.1221. [DOI] [PubMed] [Google Scholar]
  10. Kaye S., Loveday C., Tedder R. S. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J Med Virol. 1992 Aug;37(4):241–246. doi: 10.1002/jmv.1890370402. [DOI] [PubMed] [Google Scholar]
  11. Kellam P., Larder B. A. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother. 1994 Jan;38(1):23–30. doi: 10.1128/aac.38.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kellam P., Larder B. A. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol. 1995 Feb;69(2):669–674. doi: 10.1128/jvi.69.2.669-674.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kusumi K., Conway B., Cunningham S., Berson A., Evans C., Iversen A. K., Colvin D., Gallo M. V., Coutre S., Shpaer E. G. Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J Virol. 1992 Feb;66(2):875–885. doi: 10.1128/jvi.66.2.875-885.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Larder B. A., Kellam P., Kemp S. D. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS. 1991 Feb;5(2):137–144. doi: 10.1097/00002030-199102000-00002. [DOI] [PubMed] [Google Scholar]
  15. López-Galíndez C., Rojas J. M., Nájera R., Richman D. D., Perucho M. Characterization of genetic variation and 3'-azido-3'-deoxythymidine- resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4280–4284. doi: 10.1073/pnas.88.10.4280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mayers D. L., McCutchan F. E., Sanders-Buell E. E., Merritt L. I., Dilworth S., Fowler A. K., Marks C. A., Ruiz N. M., Richman D. D., Roberts C. R. Characterization of HIV isolates arising after prolonged zidovudine therapy. J Acquir Immune Defic Syndr. 1992;5(8):749–759. [PubMed] [Google Scholar]
  17. Meyerhans A., Vartanian J. P., Wain-Hobson S. DNA recombination during PCR. Nucleic Acids Res. 1990 Apr 11;18(7):1687–1691. doi: 10.1093/nar/18.7.1687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nguyen M. H., Schinazi R. F., Shi C., Goudgaon N. M., McKenna P. M., Mellors J. W. Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines. Antimicrob Agents Chemother. 1994 Oct;38(10):2409–2414. doi: 10.1128/aac.38.10.2409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Peden K., Emerman M., Montagnier L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology. 1991 Dec;185(2):661–672. doi: 10.1016/0042-6822(91)90537-l. [DOI] [PubMed] [Google Scholar]
  20. Richman D. D., Guatelli J. C., Grimes J., Tsiatis A., Gingeras T. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction. J Infect Dis. 1991 Dec;164(6):1075–1081. doi: 10.1093/infdis/164.6.1075. [DOI] [PubMed] [Google Scholar]
  21. Vartanian J. P., Meyerhans A., Asjö B., Wain-Hobson S. Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes. J Virol. 1991 Apr;65(4):1779–1788. doi: 10.1128/jvi.65.4.1779-1788.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES